Nocturnal asthma: underlying mechanisms and treatment.
Nocturnal asthma is defined by a drop in forced expiratory volume in 1 second (FEV(1)) of at least 15% between bedtime and awakening in patients with clinical and physiologic evidence of asthma. Nocturnal symptoms are a common part of the asthma clinical syndrome; up to 75% of asthmatics are awakened by asthma symptoms at least once per week, and approximately 40% experience nocturnal symptoms on a nightly basis. An extensive body of research has demonstrated that nocturnal symptoms such as cough and dyspnea are accompanied by increases in airflow limitation, airway hyperresponsiveness, and airway inflammation. Treatment strategies in nocturnal asthma are similar to those used in persistent asthma, although dosing of medications to target optimum delivery during periods of nocturnal worsening is beneficial.
Sutherland
E Rand
ER
National Jewish Medical and Research Center and University of Colorado Health Sciences Center, 1400 Jackson Street, Room J-217, Denver, CO 80206, USA. sutherlande@njc.org
D001249:Asthma / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D002940:Circadian Rhythm / Q000502:physiology*; D005541:Forced Expiratory Volume; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009569:Nitric Oxide / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000032:analysis; D011965:Receptors, Glucocorticoid / Q000032:analysis
D011943:Receptors, Adrenergic, beta; D011965:Receptors, Glucocorticoid; D009569:Nitric Oxide; D006854:Hydrocortisone